TWO · 7427.TWO
Great Novel Therapeutics Biotech & Medicals
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
Loading market information…
TWO · 6872.TWO · TWD
Stock price
Quote as of Oct 30, 2026, 05:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · TWD. Historical prices are not a forecast.
NaviFUS Corp.’s quoted price sits in the lower half of its reported 52-week range, 30.87% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
NaviFUS Corporation operates within the medical device sector, specializing in the development and commercialization of advanced focused ultrasound (FUS) technologies tailored for neurological applications. The company's primary offering is NaviFUS, a sophisticated transcranial FUS system precisely guided by neuronavigation. This innovative system is engineered to deliver concentrated energy to deep brain regions, supporting a range of clinical interventions such as enhanced drug delivery, neuromodulation, and immuno-stimulation. Additionally, NaviFUS Corp. provides NAVIRFA, a sophisticated navigation system that utilizes optical three-dimensional surgical tracking technology. Its purpose is to accurately monitor the exact placement of needle tips during various ultrasonic interventional procedures. Founded in 2015, the company's headquarters are located in Taipei, Taiwan.
Latest available per-share figures in TWD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
NT$64.00+NT$0.90 (+1.43%)
Great Novel Therapeutics Biotech & Medicals’s quoted price sits in the upper half of its reported 52-week range, 22.71% below the high.
NT$20.00-NT$0.50 (-2.44%)
Abnova (Taiwan) Corporation’s quoted price sits in the lower half of its reported 52-week range, 31.39% below the high.
NT$22.55-NT$0.35 (-1.53%)
Bio Preventive Medicine Corp.’s quoted price sits in the lower half of its reported 52-week range, 50.98% below the high.
NT$23.00NT$0.00 (0.0%)
LabTurbo Biotech Corporation’s quoted price sits in the lower half of its reported 52-week range, 11.88% below the high.
NT$13.80-NT$0.20 (-1.43%)
MegaPro Biomedical Co., Ltd’s quoted price sits in the upper half of its reported 52-week range, 19.06% below the high.
NT$14.90-NT$0.40 (-2.61%)
Enimmune corporation’s quoted price sits in the lower half of its reported 52-week range, 33.92% below the high.
NT$30.00-NT$0.40 (-1.32%)
BiOptic Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.78% below the high.
NT$16.35-NT$0.30 (-1.8%)
GeneReach Biotechnology Corp.’s quoted price sits in the lower half of its reported 52-week range, 36.99% below the high.
